Calliditas: Travere Therapeutics is advancing the US launch of FILSPARI - Redeye

Following the FDA approval in 17th February earlier this year FILSPARI is recording sales of USD 3m in Q1 (commercially available in 27th February) and USD 3.5m during the Q2. This is slightly below consensus and significantly below the initial launch recorded by Calliditas TARPEYO initial sales but still a respectable start in our view.

Länk till analysen i sin helhet: https://www.redeye.se/research/927325/calliditas-travere-therapeutics-is-advancing-the-us-launch-of-filspari?utm_source=finwire&utm_medium=RSS